Lupus nephritis is a type of inflammation which is caused by an autoimmune disease, systemic lupus erythematosus. The body’s own cells are attacked by body’s immune system due to the formation of autoantibodies, in the case of systemic lupus erythematosus. The signs and symptoms of lupus nephritis include foamy urine, high blood pressure, and edema in legs, face, feet, and ankles. Kidney problems also occur in patients with lupus nephritis that can cause fever, muscle pain, red rashes, and joint pain. Systemic lupus erythematosus can affect skin, kidney, pericardium, nervous system and lungs. It has been observed that women are much susceptible to systemic lupus erythematosus than men. Astellas Pharma, Inc. is in the process of developing tacrolimus as an immunosuppressive drug for the treatment of lupus nephritis. Human Genome Sciences, Inc. is in the process of developing belimumab as a B-lymphocyte stimulator for the treatment of lupus nephritis. Some of the companies having the pipeline of lupus nephritis include Human Genome Sciences, Inc., AstraZeneca plc, Asahi Kasei Pharma Corporation, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.